Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 known ✓ | P30531 | 2/20 | 0.63 |
| ▸ | PARP1 known ✓ | P09874 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.96 |
| ▸ | MAPT | P10636 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | ATM | Q13315 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.63 |
| ▸ | NOS2 | P35228 | 2/20 | 0.61 |
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | GLI1 | P08151 | 1/20 | 0.41 |
| ▸ | CPN1 | P15169 | 2/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2144598 | 1.00 | KDM4E (0.96) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL4636135 | 1.00 | KDM4E (0.96) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL4431863 | 1.00 | KDM4E (0.96) | KDM4EMAPTKMT2AATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL2144603 | 1.00 | KDM4E (0.96) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL440540 | 0.98 | — | — | |
| SCHEMBL1405881 | 0.98 | — | — | |
| SCHEMBL1970431 | 0.98 | — | — | |
| SCHEMBL5554688 | 0.91 | KDM4E (0.88) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL4705489 | 0.91 | KDM4E (0.88) | KDM4EMAPTKMT2AATMCYP2D6 | |
| SCHEMBL29068616 | 0.89 | KDM4E (0.84) | KDM4EMAPTKMT2AATMCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | VTV THERAPEUTICS LLC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | VTV THERAPEUTICS LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | VTV THERAPEUTICS LLC | 2023-03-23 | — | — | US | disclosed |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | VTV THERAPEUTICS LLC | 2021-11-04 | — | — | US | disclosed |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2021-03-11 | — | — | US | disclosed |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2021-01-26 | — | — | US | disclosed |
| US-10888569-B1 | Methods and compositions for treating cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-01-12 | — | — | US | disclosed |
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | VTV THERAPEUTICS LLC (US) | 2019-11-05 | — | — | US | disclosed |
| EP-2858986-B1 | PIPERIDINE DERIVATIVES AS GPR119 AGONISTS | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2019-10-30 | — | — | EP | disclosed |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | VTV THERAPEUTICS LLC | 2019-03-14 | — | — | US | disclosed |
| CN-102203093-B | Aminotriazolopyridines and their use as kinase inhibitors | SIGNAL PHARM LLC | 2015-05-13 | — | — | CN | disclosed |
| EP-2858986-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | Chong Kun Dang Pharmaceutical Corp. (KR) | 2015-04-15 | — | — | EP | disclosed |
| CN-104364246-A | Piperidine derivatives useful as GPR119 agonists | TOYOTA MOTOR CO LTD | 2015-02-18 | — | — | CN | disclosed |
| WO-2013187646-A1 | PIPERIDINE DERIVATIVES FOR GPR119 AGONIST | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2013-12-19 | — | — | WO | disclosed |
| US-8445501-B2 | Substituted 7-carboxamido-pyrrolo[3,2-d]pyrimidines | TAKEDA GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2247594-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | Nycomed GmbH (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
| WO-2009106531-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10463652-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | SLC6A1 4045/4885PARP1 1374/4885KDM4E 2569/4885 |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | SLC6A1 4619/4885PARP1 710/4885KDM4E 1965/4885 |
| US-20210338644-A1 | Substituted Fused Imidazole Derivatives and Methods of Treating Sickle Cell Disease and Related Complications | HBB, HBG1, HBG2 | SLC6A1 305/4885PARP1 3314/4885KDM4E 3590/4885 |
| US-20260027090-A1 | Methods of Inhibiting Osteoclastogenesis and Osteoclast Activity | CSF1R, CD209, NFATC1 | SLC6A1 1859/4885PARP1 2904/4885KDM4E 276/4885 |
| US-20190076410-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | SLC6A1 4045/4885PARP1 1374/4885KDM4E 2569/4885 |
| US-10898475-B2 | Bach1 inhibitors in combination with Nrf2 activators and pharmaceutical compositions thereof | BACH1, KEAP1, NFE2L2 | SLC6A1 3634/4885PARP1 1052/4885KDM4E 2430/4885 |
| US-20230093476-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING REFRACTIVE OCULAR DISORDERS | ALDH1A2, UACA, PDE6D | SLC6A1 284/4885PARP1 1227/4885KDM4E 2615/4885 |
| US-20260034107-A1 | SUBSTITUTED FUSED IMIDAZOLE DERIVATIVES AND METHODS OF TREATING SICKLE CELL DISEASE AND RELATED COMPLICATIONS | HBB, HBZ, HBG1 | SLC6A1 87/4885PARP1 3837/4885KDM4E 1499/4885 |
| US-20210069159-A1 | Bach1 Inhibitors in Combination with Nrf2 Activators and Pharmaceutical Compositions Thereof | BACH1, KEAP1, NFE2L2 | SLC6A1 3238/4885PARP1 488/4885KDM4E 2711/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | SLC6A1 4619/4885PARP1 710/4885KDM4E 1965/4885 |
| US-10888569-B1 | Methods and compositions for treating cancer | BACH1, BCOR, BCCIP | SLC6A1 3902/4885PARP1 987/4885KDM4E 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.